ID reflex to NeoTYPE® enhancements and New York availability:
NeoGenomics and Biotheranostics, Inc. provide a combined test offering for
metastatic cancer patients with an unknown or unclear diagnosis. CancerTYPE ID®
with reflex to NeoTYPE® Cancer Profile enables tumor type
classification and identification of actionable biomarkers in a seamless,
Effective Monday, August 1, we have enhanced the biomarker testing
follow-up performed for many of the tumor types classified by CancerTYPE ID®.
Also, we are pleased to make CancerTYPE ID® with reflex to NeoTYPE®
available to our New York clients for the first time.
With these revisions, we have expanded gene fusion coverage; created more
precise follow-up test combinations for bladder, brain, prostate, and salivary
gland; and added the first hematologic tumor profile (NeoTYPE®
Lymphoma) to the service. Please see more here
about taking this single testing path to establish a diagnosis and care
options. Our Online Orders system and printed
solid tumor NGS requisitions are ready for orders from all clients.
CancerTYPE ID® is
performed and billed separately by NeoGenomics’ contracted reference
laboratory, Biotheranostics, Inc., an independent CLIA-licensed and
CAP-accredited reference laboratory. Please see www.cancertypeid.com
for more details.
FISH: JUL - DEC 2022 Assessment
Available Now: The Jul - Dec 2022 assessment for HER2 breast FISH that
tech-only clients can utilize is now available in NeoUniversity™.
NeoGenomics offers world-class educational programs as an additional benefit to
all of our clients. Please visit NeoUniversity™
for more information.
For interface-related test
changes that took effect on Monday July 18th, click here
for a downloadable document to view the impacted interface test codes.
***Effective Immediately July 27th*** Extended Leukemia/Lymphoma Panel will NOT be available for
orders until further notice. See downloadable document for further details.
New York Clients can order now order this test code through the interface:
CancerTYPE ID® (w/ NTP based on CTID result)
If you have interface
questions, please contact InterfaceTeam@Neogenomics.com